Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.63
AFFX's Cash to Debt is ranked higher than
61% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. AFFX: 0.63 )
AFFX' s 10-Year Cash to Debt Range
Min: 0.19   Max: 15.67
Current: 0.63

0.19
15.67
Equity to Asset 0.56
AFFX's Equity to Asset is ranked higher than
69% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. AFFX: 0.56 )
AFFX' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.95
Current: 0.56

0.22
0.95
Interest Coverage 0.33
AFFX's Interest Coverage is ranked lower than
55% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 257.77 vs. AFFX: 0.33 )
AFFX' s 10-Year Interest Coverage Range
Min: 0.27   Max: 37.16
Current: 0.33

0.27
37.16
F-Score: 6
Z-Score: 2.24
M-Score: -3.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 0.61
AFFX's Operating margin (%) is ranked higher than
72% of the 249 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.55 vs. AFFX: 0.61 )
AFFX' s 10-Year Operating margin (%) Range
Min: -254.35   Max: 17.26
Current: 0.61

-254.35
17.26
Net-margin (%) -1.10
AFFX's Net-margin (%) is ranked higher than
72% of the 249 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.38 vs. AFFX: -1.10 )
AFFX' s 10-Year Net-margin (%) Range
Min: -232.61   Max: 17.9
Current: -1.1

-232.61
17.9
ROE (%) -1.42
AFFX's ROE (%) is ranked higher than
72% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. AFFX: -1.42 )
AFFX' s 10-Year ROE (%) Range
Min: -68.27   Max: 22.99
Current: -1.42

-68.27
22.99
ROA (%) -0.78
AFFX's ROA (%) is ranked higher than
74% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. AFFX: -0.78 )
AFFX' s 10-Year ROA (%) Range
Min: -33.34   Max: 10.32
Current: -0.78

-33.34
10.32
ROC (Joel Greenblatt) (%) 3.08
AFFX's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. AFFX: 3.08 )
AFFX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -128.18   Max: 80.9
Current: 3.08

-128.18
80.9
Revenue Growth (3Y)(%) 8.20
AFFX's Revenue Growth (3Y)(%) is ranked higher than
82% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. AFFX: 8.20 )
AFFX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -33.6   Max: 102.9
Current: 8.2

-33.6
102.9
EBITDA Growth (3Y)(%) 52.40
AFFX's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. AFFX: 52.40 )
AFFX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -24.4   Max: 52.4
Current: 52.4

-24.4
52.4
EPS Growth (3Y)(%) -50.00
AFFX's EPS Growth (3Y)(%) is ranked higher than
55% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. AFFX: -50.00 )
AFFX' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.3   Max: 25.1
Current: -50

-55.3
25.1
» AFFX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

AFFX Guru Trades in Q1 2014

Joel Greenblatt 151,285 sh (+385.09%)
Paul Tudor Jones 56,400 sh (+15.87%)
PRIMECAP Management 10,690,540 sh (+0.22%)
Murray Stahl 104,000 sh (unchged)
Jim Simons 769,223 sh (-25.50%)
Chuck Royce 90,000 sh (-30.77%)
» More
Q2 2014

AFFX Guru Trades in Q2 2014

Chuck Royce 90,000 sh (unchged)
Murray Stahl 104,000 sh (unchged)
PRIMECAP Management 10,559,240 sh (-1.23%)
Joel Greenblatt 72,552 sh (-52.04%)
Paul Tudor Jones 20,400 sh (-63.83%)
Jim Simons 198,280 sh (-74.22%)
» More
Q3 2014

AFFX Guru Trades in Q3 2014

Jim Simons 576,885 sh (+190.94%)
Paul Tudor Jones 29,500 sh (+44.61%)
Murray Stahl 104,000 sh (unchged)
PRIMECAP Management 10,559,240 sh (unchged)
Chuck Royce 90,000 sh (unchged)
Joel Greenblatt Sold Out
» More
Q4 2014

AFFX Guru Trades in Q4 2014

Joel Greenblatt 38,181 sh (New)
Paul Tudor Jones 30,745 sh (+4.22%)
PRIMECAP Management 10,940,040 sh (+3.61%)
Murray Stahl 104,000 sh (unchged)
Jim Simons 282,620 sh (-51.01%)
Chuck Royce 4,000 sh (-95.56%)
» More
» Details

Insider Trades

Latest Guru Trades with AFFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 34.84
AFFX's Forward P/E is ranked higher than
84% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. AFFX: 34.84 )
N/A
P/B 3.44
AFFX's P/B is ranked higher than
74% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.82 vs. AFFX: 3.44 )
AFFX' s 10-Year P/B Range
Min: 0.24   Max: 11.78
Current: 3.44

0.24
11.78
P/S 2.70
AFFX's P/S is ranked higher than
77% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.63 vs. AFFX: 2.70 )
AFFX' s 10-Year P/S Range
Min: 0.38   Max: 11.22
Current: 2.7

0.38
11.22
PFCF 26.48
AFFX's PFCF is ranked higher than
88% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. AFFX: 26.48 )
AFFX' s 10-Year PFCF Range
Min: 1.89   Max: 1220.5
Current: 26.48

1.89
1220.5
POCF 22.30
AFFX's POCF is ranked higher than
84% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 431.57 vs. AFFX: 22.30 )
AFFX' s 10-Year POCF Range
Min: 1.64   Max: 2657
Current: 22.3

1.64
2657
EV-to-EBIT 470.25
AFFX's EV-to-EBIT is ranked higher than
73% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. AFFX: 470.25 )
AFFX' s 10-Year EV-to-EBIT Range
Min: -2863   Max: 670
Current: 470.25

-2863
670
Current Ratio 2.87
AFFX's Current Ratio is ranked higher than
75% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. AFFX: 2.87 )
AFFX' s 10-Year Current Ratio Range
Min: 1.52   Max: 20.23
Current: 2.87

1.52
20.23
Quick Ratio 2.11
AFFX's Quick Ratio is ranked higher than
70% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. AFFX: 2.11 )
AFFX' s 10-Year Quick Ratio Range
Min: 1.33   Max: 19.89
Current: 2.11

1.33
19.89
Days Inventory 138.68
AFFX's Days Inventory is ranked higher than
68% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 131.99 vs. AFFX: 138.68 )
AFFX' s 10-Year Days Inventory Range
Min: 77.31   Max: 2372.5
Current: 138.68

77.31
2372.5
Days Sales Outstanding 49.04
AFFX's Days Sales Outstanding is ranked higher than
85% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 74.31 vs. AFFX: 49.04 )
AFFX' s 10-Year Days Sales Outstanding Range
Min: 49.04   Max: 114.29
Current: 49.04

49.04
114.29

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 90.79
AFFX's Price/Tangible Book is ranked higher than
55% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.60 vs. AFFX: 90.79 )
AFFX' s 10-Year Price/Tangible Book Range
Min: 0.87   Max: 75.92
Current: 90.79

0.87
75.92
Price/DCF (Projected) 2.05
AFFX's Price/DCF (Projected) is ranked higher than
88% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. AFFX: 2.05 )
AFFX' s 10-Year Price/DCF (Projected) Range
Min: 0.42   Max: 26.68
Current: 2.05

0.42
26.68
Price/Median PS Value 1.53
AFFX's Price/Median PS Value is ranked higher than
63% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. AFFX: 1.53 )
AFFX' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 22.81
Current: 1.53

0.31
22.81
Earnings Yield (Greenblatt) 0.20
AFFX's Earnings Yield (Greenblatt) is ranked higher than
71% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. AFFX: 0.20 )
AFFX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 387
Current: 0.2

0.1
387
Forward Rate of Return (Yacktman) -7.88
AFFX's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.73 vs. AFFX: -7.88 )
AFFX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.7   Max: 12.2
Current: -7.88

-19.7
12.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AFF.Germany,
Affymetrix Inc was incorporated in California in 1992 and reincorporated in Delaware in 1998. The Company is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Companys operations consist of two reportable segments, Affymetrix Core and eBioscience. Affymetrix Core is divided into three business units with each business unit having its own research, development and marketing groups to better serve customers and respond quickly to the market needs. The three business units that form Affymetrix Core are; Expression, Genetic Analysis and Clinical Applications, and Life Science Reagents. Expression: This business unit develops and markets the Company's GeneChip gene expression products and services, and the QuantiGene line of low-to-mid-plex RNA measurement products; Genetic Analysis and Clinical Applications. This business unit develops and markets the Company's genotyping, such as the Axiom product line and clinical research applications, such as the CytoScan cytogenetics; Life Science Reagents; This business unit develops and sells reagents, enzymes, purification kits and biochemicals used by life science researchers. eBioscience; This reportable segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company markets and distributes its products directly to customers in North America, Japan and major European markets. The Company is facing competition as existing companies develop new or improved products, and as companies enter the market with new technologies, such as next-generation sequencing. In the highly multiplexed genotyping and gene expression markets, existing competitive technologies include DNA sequencing, which the Company does not offer and is offered by companies such as Illumina, Inc., Life Technologies Corporation and Pacific Biosciences of California, Inc. The Companys operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations.
» More Articles for AFFX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: PXLW, NGPC, MS, CHMT, AFFX Aug 15 2011 
Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 5,000 Shares Nov 19 2010 
Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 10,000 Shares Aug 24 2010 
Weekly CFO Buys Highlight: AspenBio Pharma, Solarwinds, Affymetrix, Cascade Financial Corp., Bank of Aug 01 2010 
Weekly CFO Buys Highlight: Ocean BioChem, Solarwinds Inc., PDL BioPharma, Autobytel Inc., Affymetrix May 09 2010 
Affymetrix Inc. Reports Operating Results (10-Q) May 06 2010 
Weekly CFO Buys Highlight: Ocean BioChem, Affymetrix, Richardson Electronics, First Defiance Financi May 02 2010 
Affymetrix Reports Fourth Quarter and Fiscal Year 2008 Results Jan 28 2009 
Affymetrix to Host Conference Call on January 28, 2009 to Announce Fourth Quarter and Fiscal 2008 Re Jan 28 2009 
Weekly CEO Buys Highlight: ScheringPlough Corp., Novellus Systems Inc., SeaBright Insurance Holdings May 01 2008 

More From Other Websites
Coherus Biosciences (CHRS) Jumps: Stock Moves Up 6.2% - Tale of the Tape Mar 25 2015
Myriad Poised on Portfolio Strength Despite Y/Y Downfall in Q2 - Analyst Blog Mar 23 2015
Celgene Presents Efficacy, Safety Data on Otezla - Analyst Blog Mar 23 2015
Biogen Idec (BIIB) Worth Watching: Stock Rises 9.8% - Tale of the Tape Mar 23 2015
Illumina (ILMN) Files NIPT Patent Infringement Suit in UK - Analyst Blog Mar 20 2015
Sanofi Inks Multi-Component Strategic Deal with Evotec - Analyst Blog Mar 20 2015
Theravance/Glaxo's Breo Ellipta Gets Mixed FDA Panel View - Analyst Blog Mar 20 2015
Pfizer Announces Publication of CAPiTA Data on Prevenar 13 - Analyst Blog Mar 19 2015
Celgene's Data on Crohn's Disease Candidate Published - Analyst Blog Mar 19 2015
Healthways (HWAY) Rides High on Strategic Partnerships - Analyst Blog Mar 19 2015
PerkinElmer: 52-Week High on Solid Q4, Positive 2015 View - Analyst Blog Mar 19 2015
Juno Therapeutics' (JUNO) Q4 Loss Wider than Expected - Analyst Blog Mar 19 2015
Mirati Therapeutics (MRTX) Jumps: Stock Moves Up 6.8% - Tale of the Tape Mar 19 2015
Genomic Health Prostrate Cancer Test Grows but Hits Margins - Analyst Blog Mar 18 2015
Nektar's Breast Cancer Candidate Fails in BEACON Study - Analyst Blog Mar 18 2015
CorMedix (CRMD) Looks Good: Stock Moves 8.7% Higher - Tale of the Tape Mar 18 2015
Fresenius Medical: 52-Week High on Solid Q4, Bright View - Analyst Blog Mar 17 2015
The Cooper Companies Seeks License Option from EP Global - Analyst Blog Mar 17 2015
Is Affymetrix (AFFX) Stock a Solid Choice Right Now? - Tale of the Tape Mar 17 2015
Alere (ALR) Touches 52-Week High on Portfolio Expansion - Analyst Blog Mar 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK